Press Release

Zetagen Therapeutics, Inc. Secures $5.34 Million in Series A Funding to Accelerate Clinical Work

6 February 2020
  • U.S.-based biopharmaceutical company has discovered and patented a novelmolecular pathway intended to treat metastatic bone lesions
  • Series A Funding will be used for scientific infrastructure to prepare for initial human clinical study
  • Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions

February 6, 2020 – (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced the close of $5.34M Series A funding round. The financing will accelerate the growth of the Company’s ongoing clinical programs for ZetaMet™ (Zeta-BC-003), a synthetic, small-molecule, inductive biologic being developed to target and resolve metastatic lesions while inhibiting future tumor growth.

“We are extremely pleased to have reached such an important milestone in Zetagen’s advancement as a biopharmaceutical company, ” said Joe C. Loy, CEO of Zetagen Therapeutics, Inc. “This funding is paramount to accelerating our clinical programs around ZetaMet™ (Zeta-BC-003) by adding the necessary scientific infrastructure that will allow us to prepare for future human clinical trials.”

ZetaMet™ (Zeta-BC-003) is a novel molecular pathway paired with a proprietary, drug-eluting implant technology. The novel therapy is designed to resolve tumor growth, inhibit pain, and regenerate bone. Zetagen exclusively licensed the platform technology from the State University of New York in 2016.

All News

About zetagen Therapeutics

Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs.

The company's pipeline encompasses several oncological candidates targeting metastatic and primary cancers for breast, lung, brain, prostate, and sarcomas with such drugs as ZetaMet™ (Zeta-BC-003), ZetaMet-P™ (Zeta-PC-004) and ZetaMAST™ (Zeta-MBC-005).

Forward-Looking Statements

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.
Source: Zetagen Therapeutics, Inc.
SUNY Biotech Accelerator
841 E Fayette Street, Suite 1100
Syracuse, NY 13210
Investor Inquiries:
Zetagen Therapeutics, Inc.
Email: InvestorRelations@zetagen.com

Media Inquiries:
Mog & Springer Communications on Behalf of Zetagen Therapeutics, Inc.
Elizabeth Harness, Principal
Email: elizabeth.harness@mogandspringer.com
Phone: +1-585-435-7379